TY - JOUR T1 - Correspondence on ‘Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial’ JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e250 LP - e250 DO - 10.1136/annrheumdis-2020-218911 VL - 81 IS - 12 AU - Markus Bredemeier Y1 - 2022/12/01 UR - http://ard.bmj.com/content/81/12/e250.abstract N2 - The Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial,1 published in May 2019 in New England Journal of Medicine, analysed the efficacy and safety of nintedanib in the treatment of systemic sclerosis-related interstitial lung disease (SSc-ILD) over 52 weeks. A reanalysis of the safety and tolerability data was recently published in Annals of the Rheumatic Diseases.2 In both articles, we could not find information on the incidence of serious infections and serious respiratory tract infections.Further safety results of the SENSCIS trial, using a wider time frame than the original publications (i.e., up to 100 weeks of follow-up), are accessible at ClinicalTrials.gov website since December 2019.3 In a closer look at the … ER -